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http://www.virologyj.com/content/11/1/130RESEARCH Open AccessThe CD8 Antiviral Factor (CAF) can suppress
HIV-1 transcription from the Long Terminal
Repeat (LTR) promoter in the absence of
elements upstream of the CATATAA box
Varsha Shridhar1,2, Yue Chen2 and Phalguni Gupta2*Abstract
Background: The CD8 Antiviral Factor (CAF) suppresses viral transcription from the HIV-1 Long Terminal Repeat
(LTR) promoter in a non-cytolytic manner. However, the region on the LTR upon which CAF acts is unknown.
Our objective was to determine the region on the LTR upon which CAF acts to suppress HIV-1 transcription.
Methods: Serial deletions of the LTR from the 5’ end and inactivating point mutations were made.
Results: Serial deletions of the LTR from the 5’ end indicated the importance of a short ~120 bp segment,
containing the 3 SpI sites, CATA box (used by HIV-1 instead of the TATA box) and TAR region, in the suppressive
process. Introduction of deletions or inactivating point mutations in the SpI sites or deletion of the TAR region did
not abolish CAF-mediated transcriptional suppression. Yet, CAF-mediated transcriptional suppression was still
retained in the HIV-1 CATA-TAR segment.
Conclusion: CAF is able to suppress transcription from the LTR lacking all the elements upstream of the CATA box.
Our results suggest that the HIV-1 CATA box may be responsible for CAF-mediated suppression of transcription
from the HIV-1 LTR.
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CD8+ T cells can control HIV-1 replication by non-
cytolytic mechanisms [1,2]. The first non-cytolytic anti-
viral CD8+ T cell response was described in Long Term
Non-Progressers of HIV-1 infection [1] and the factor
mediating it was termed “CD8 Antiviral Factor” (CAF)
[3]. CAF-mediated antiviral response has several charac-
teristics: First, CAF suppresses HIV-1 mRNA production
[4-8]. Second, CAF activity is not MHC-restricted or
does not require direct contact between the CD8+ T cell
and the target cell [9,10]. Third, CAF has been found to
be effective against a wide range of HIV-1 clades, as well
as HIV-2 and SIV and its activity inversely correlates* Correspondence: pgupta1@pitt.edu
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unless otherwise stated.with the stage of disease [11-18], and finally, both HIV-1
R5 and X4 viruses can be equally well suppressed
[19-21]. Although many non-cytolytic CD8+ T cell factors
have since been described [2,22-24], the identity and
mechanism of action of CAF are as yet unknown.
The aim of this study was to elucidate the mechani-
sm by which CAF mediates its HIV-1 transcription-
suppressing effects. We hypothesized that CAF acts on
and induces changes in the viral promoter to suppress
transcription. Towards this, we focused on determining
the region in viral promoter that was crucial for the sup-
pressive effect of CAF. We performed serial progressive
deletions on the LTR at 5’ end to identify the minimal
region required for CAF-mediated transcriptional sup-
pression. By a process of eliminating likely candidates, our
data suggest that the HIV-1 CATA box (used by HIV-1 in-
stead of the TATA box, motif: CATATAA, ref [25]) is the
target for transcriptional suppression by CAF.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CAF is HIV-1 LTR specific
CAF has been shown to reduce the amount of HIV
mRNA in infected CD4+ T cells [5]. We first sought to
determine if the action of CAF was specific to a trans-
fected HIV-1 LTR plasmid or if CAF could also act upon
other transfected viral promoters. When 293 T cells,
treated with CAF from the CD8+ T cells of an HIV-1 in-
fected individual or with media control, were transfected
with CMV-CAT (CAT = chloramphenicol acetyltransfer-
ase, a reporter gene), SV40-luciferase or HIV LTR-CAT
constructs, we found that CAF was able to completely
suppress reporter protein production in cell transfected
with the full length HIV-1 LTR construct (referred to as
“wt (FL)” in the figure) (Figure 1A). However, CAF did
not suppress reporter-protein production in cells trans-
fected with the CMV or SV40 constructs (Figure 1B). In
all cases, MTT assays showed no cell death in CAF-
treated and control cells (data not shown).
Thus, CAF seems to be specific to HIV. CAF might
act by changing protein-DNA interactions or makeA
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Figure 1 Transcriptional suppression of HIV-1 LTR deletion mutants b
with Hanks Buffer (-CAF) or conditioned culture medium from a transforme
(wt (FL)) HIV-1 LTR-CAT (Panel A) or CMV-CAT (Panel B, Left ) or SV40-lucif
independent experiments conducted in triplicate. *, p < 0.05; ns, not signifiepigenetic modifications to the HIV-1 LTR promoter. A
previous paper [26] examined the effect of deletions and
inactivating point mutations in certain regulatory ele-
ments and transcription factor binding sites on the HIV-1
LTR on the ability of CAF to suppress viral transcription.
Their results showed that the replication of full-length
HIV-1 molecular clones bearing mutations and deletions
in individual transcription factor binding sites could still
be suppressed in the presence of CAF. However, the au-
thors did not study the effect of abolishing more than 1
promoter element simultaneously. We explored the possi-
bility that more than one transcription factor-binding site
or regulatory element on the viral promoter might be sim-
ultaneously involved in the process of CAF-mediated
HIV-1 transcriptional suppression. The main segments of
the LTR studied were the Negative Regulatory Element
(NRE), the 2 NFKB sites, the 3SpI sites, and the CATA
box in the U3 region, and the TAR bulge-and-loop,
present in the R region (Figure 2). CAF might also func-
tion by making epigenetic modifications to the LTR.
However, in this study, we did not examine the epigeneticBstNI HaeIII
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Figure 2 Schematic of the HIV-1 Long Terminal Repeat (LTR) promoter showing the main transcription regulatory sites. NRE, Negative
Regulatory Region, NFKB, SpI sites, TATA box and TAR. EcoRV (-119), BstNI (-83), HaeIII (-69) and MnlI (-31) refer to the positions of the restriction
enzyme site used to cleave the Wt full length LTR.
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DNA.
LTR progressive deletion constructs narrow the region of
the promoter needed for CAF action
We used constructs that had been deleted of these re-
gions from the HIV-1 LTR to investigate the possibility
of multiple transcription factor (TF)-binding sites acting
in conjunction with each other to suppress transcription
in response to CAF. These constructs have been de-
scribed before [27] and include the full length Wt-LTR,
the EcoRV construct (containing deletion of the NRE),
the BstNI construct (containing deletions up to the SpI
sites), and the HaeIII construct (deletions up to the 3rd
Sp1 site and containing the 2 SpI sites most proximal to
the CATA box, the TATA box and the TAR region).
They were transfected into 293 T cells treated with ei-
ther CAF or media control, and then stimulated with
PMA. We found that CAF was able to suppress reportergene expression from all of these constructs (Figure 1A).
Sequential deletions of the LTR actually had higher tran-
scriptional rates compared to the full-length promoter.
This might be because of removal of negative regulatory
regions from the LTR, leading to higher basal transcrip-
tion in the absence of CAF.
These results indicate that CAF-mediated suppression
of transcription is specific to HIV-1, is not affected by
the type of reporter gene, and that the region encom-
passing the -69 to +83 of the LTR, containing 3 SpI sites,
CATA box and the TAR region, is sufficient for the sup-
pressive action of CAF.
Role of the TAR loop in conferring susceptibility to CAF
The TAR region is a very attractive candidate target for
CAF action. It has a unique bulge-loop structure and is
well-conserved across all clades of HIV-1 [28]. Critical
interactions between the TAR and the viral transactiva-
tor protein Tat take place on the bulge-loop structure on
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Figure 3 Role of TAR in CAF suppression of HIV-1 LTR.
Schematic of the TAR from HIV-1 LTR with the arrows indicating the
sites at which it was cleaved, and the shadow, the intervening region
that was deleted (Panel A). Reporter gene product (CAT) expression in
cells pretreated with Hanks buffer (-CAF) or conditioned culture
medium from a transformed CD8+ T cell line (+CAF) and
transfected with the BstdelTAR construct, containing 3 SpI sites and
TATA box (Panel B) Results are representative from at least 2
independent experiments conducted in triplicate. *, p < 0.05; ns,
not significant.
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help explain the specificity of CAF for HIV. Previous in-
vestigations on the region of the LTR necessary for CAF
action probed the role of TAR by introducing inactivating,
point mutations to disrupt the Tat-TAR interaction axis
[26]. But if the structure of TAR, and not its sequence,
were important for CAF action, point mutations might
not indicate the importance of TAR in suppression.
For further scrutiny of the TAR, we selected the BstNI
construct, which contains all the 3 SpI sites, HIV-1
CATA box and TAR regions. We deleted the bulge-loop
region of the TAR (shaded in Figure 3A) from the BstNI
construct, to form a new construct called BstΔTAR, to
evaluate any changes in susceptibility to CAF. We found
that, contrary to previous studies showing that the dele-
tion of TAR drastically reduces the transcriptional ability
of LTR [31,32], the TAR deleted BstΔTAR construct was
still transcriptionally active and moreover, was suppressed
by CAF (Figure 3B).
Role of the SpI sites in CAF-mediated suppression
We then sought to determine if the 3 SpI-CATA seg-
ment of HIV-1 LTR could independently transcribe and
get suppressed in response to CAF, in the absence of any
other enhancer or promoter elements or the TAR se-
quence. Hence, we inserted the 3 SpI-CATA segment,
which constitutes the HIV-1 minimal promoter, up-
stream of the luciferase reporter gene in a promoter-less
vector, pGL4.10 and determined if it could independ-
ently transcribe. We found that the resultant construct
could undergo LTR-driven transcription in response to
PMA. Addition of CAF from transformed CD8+ T cell
culture supernatants as well as CAF from primary CD8+
T cells from an HIV-1 infected individual (referred to as
CAFprimary) suppressed transcription from this construct
efficiently (Figure 4A).
Next, we deleted each SpI site individually or in pairs, in
the absence of TAR, to check for changes in response to
CAF. We found that deletion of the different SpI sites had
different effects on LTR-driven transcription (Figure 4B).
Deletion of SpI (1) or (2) still retained transcription, while
deletion of SpI (3) or both (1) and (2) abolished transcrip-
tion. However, as long as any construct was able to tran-
scribe, it was suppressed by CAF. Since suppression of
transcription is inextricably linked with the ability of the
construct to transcribe, it was not possible to measure
suppression in those constructs that were transcriptionally
inactive.
To confirm that the results we observed were a product
of SpI site inactivation and not because of the deletion
process itself, we next inactivated the SpI sites by point
mutation. Inactivation of the SpI sites, either individually
or in pairs, resulted when key G residues in the SpI bind-
ing sites were replaced with T. Mutation of the SpI sitesdid not transcriptionally inactivate the construct, in ac-
cordance with previous reports [33]. While mutation of
the various SpI sites was seen to affect transcription, all
constructs were able to get suppressed in response to
CAF (Figure 4C).
Role of the CATA-box in CAF mediated HIV-1 suppression
Our results with the TAR and SpI deletions/mutations
have shown that none of these regions is required for
transcriptional suppression. This points towards the
CATA box as being important for this process. We
attempted to delineate the role of the CATA box by ex-
changing the CMV TATA box with that of HIV-1 in an
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Figure 4 (See legend on next page.)
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Figure 4 Role of Sp1 sites in CAF suppression of transcription of HIV-1 LTR. Suppression of reporter gene product (luciferase) expression in
cells pretreated with Hanks buffer (-CAF) or conditioned culture medium from a transformed CD8+ T cell line (+CAF) and transfected with a
construct containing only the 3Sp1 sites and TATA box of HIV-1 LTR. (Panel A) Reporter gene product (CAT) expression in cells pretreated with
Hanks buffer (-CAF) or conditioned culture medium from a transformed CD8+ T cell line (+CAF) and transfected with Sp1 deletion constructs
(Panel B) or SpI mutated constructs (Panel C). The position of the specific Sp1 either deleted or mutated is given by the number on the x axis.
The sequence in Panel C shows the bases (in bold) that were mutated to inactivate the SpI sites (underlined). CAF-primary refers to conditioned
culture media from primary CD8+ T cells from an HIV infected individual Results are representative from 2 independent experiments conducted
in triplicate. *, p < 0.05.
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Figure 5 Transcription of TATA-TAR construct is suppressed by
CAF. Reporter gene product (CAT) expression in cells pretreated with
Hanks buffer (-CAF) or conditioned culture medium from a transformed
CD8+ T cell line (+CAF) and transfected with a construct containing
only the TATA box and TAR from HIV-1 LTR, in the presence or absence
of the HSV-1 ICP0 protein. Transcription from the LTR was driven
either by CMV-Tat (Panel A) or addition of PMA (Panel B) Results are
representative of 2 independent experiments conducted in triplicate.
*, p < 0.05.
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with an HIV-1 CATA box, but both of these were tran-
scriptionally inactive and could not be used to assess the
ability of CAF to suppress transcription (data not
shown). Hence, we used a HIV-1 CATA box-TAR con-
struct (called MnlI, after the restriction enzyme used to
create it, see Figure 2) to test this hypothesis. To boost
transcription, we used the Herpes virus protein ICP0,
which has been shown to increase transcription from
the LTR by interacting with Tat protein [34]. We trans-
fected cells with CATA-TAR and ICP0 constructs. Gene
expression was induced either with CMV-Tat (Figure 5A)
or PMA (Figure 5B). ICP0 was able to increase tran-
scription from the construct, and in the presence of
CAF, this transcription was suppressed. Since CAF-
mediated suppression was mediated in the absence of
the SpI sites, and since TAR [28] was previously found
not be required for the suppressive process (as seen in
Figure 3B), our results suggest that the region on the
HIV-1 LTR necessary for CAF action is likely to reside
primarily within or close to the CATA box. Studies have
shown that the HIV-1 CATA box regulates the assembly
of transcription complexes necessary for processive viral
transcription and that these complexes interact with up-
stream elements for efficient initiation and elongation of
transcripts [35]. It is possible that CAF functions by
disrupting the complexes necessary for transcription at
the CATA box. It is also possible that the upstream Sp1
sites are involved, as mutation of SpI(1) did appear to
have an effect on the ability of CAF to completely sup-
press transcription.
In conclusion, our report shows that CAF can sup-
press transcription from all regions of the HIV-1 LTR
upstream of the CATA box. We did not study epigenetic
changes or changes in the CATA-box binding proteins
on the HIV-1 LTR in response to CAF. Future work to
elucidate the mechanism of CAF in HIV-1 transcription
suppression may include these avenues.
Materials and methods
Ethical statement
No patients were specifically recruited for the purposes
of this study. The CD8+ T-cell line, TG, was previously
established by herpesvirus saimiri (HVS)-transformation
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infected subject from the Multicenter AIDS Cohort
Study (MACS) [19].
Plasmid constructs
Full length HIV-1 LTR-CAT and the successive deletion
constructs at EcoRV, BstNI, HaeIII and MnlI, previously
described [27]; the CMV-CAT and CMV-tat constructs;
and the ICP0 expression plasmid were generous gifts
from Dr. Mario Estable of Ryerson University, Toronto,
Canada, Dr. Lung-ji Chang of the University of Florida
and Dr. Paul Kinchington, from the University of Pittsburgh,
respectively. The BstΔTAR construct was made by
digesting the BstNI construct with KpnI and BglII,
blunting the ends with Klenow and then ligating the
product with T4 DNA ligase. The SV40-luciferase con-
struct was made by PCR-amplifying the SV40 early pro-
moter out from the pSV-beta galactosidase control vector
(Promega, WI) using the primers Fwd- ATTAGATCTGC
GCAGCACCATG and Rev- CCAGCAGAGATCCCAAG
CTTTTT, digesting the PCR product with the enzymes
BglII and HindIII followed by ligation to pGL4.10 (Pro-
mega, WI) cut with the same enzymes. The CMV-TAR
construct was made by amplifying the TAR region out of
HIV-1-LTR with the primers F:TTAGGATCCTTTAGT
GAACCGGGTCT and R:GCGGATATCTATTGAGGCT
TAAGC, digesting the PCR product with the enzymes
BamHI and EcoRV and ligating into the CMV-CAT vector
cut with the same enzymes. The 3SpI-TATA construct
was created by PCR amplifying the SpI-TATA region of
the LTR using the primers 5’ATACTCGAGAGGCGT
GGCCT and 5’TACAAGCTTCCAGAGAGACCCAGTA,
digesting the PCR product with the restriction enzymes
XhoI and HindIII, and ligating it to the pGL4.10 plas-
mid digested with the same enzymes. SpI deletion mu-
tants were created by overlapping PCR, using the
specific DNA oligonucleotides and the corresponding
primers listed in Table 1. For the point mutations, the
mutations introduced to inactivate the SpI sites (italics)Table 1 SpI deletion construct oligos and primers
S No Name of construct
1 Del 1, del 2 5’TCGGAGGACAGTACTCCGACCC
5’GAGCCCTCAGATCCTGCATATAAG
2 Del 1 5’TCGGAGGACAGTACTCCGACCCGGTCG
5’GAGCCCTCAGATCCTGCATATAAG
3 Del 2 5’TCGGAGGACAGTACTCCGACCCGGTC
5’GAGCCCTCAGATCCTGCATATAAG
PCR primers used for amplifying all the constructs: Fwd TGTGAAGCTTTCGGAGGACAare marked in bold, where G nucleotides were substituted
by T: TTCGTGGCCTGTTCGGGACTGGTTAGTGGC.
The oligonucleotide pairs and the corresponding primers
used to create these constructs are listed in Table 2. For
the deletion constructs, each pair of oligonucleotides was
added to a PCR mix containing dNTPs, MgCl2 and DNA
polymerase; the reaction was cycled without primers for
5 cycles, with these conditions: (94C, 2’30”; [94C-1’, 55C-1’,
72C- 1’45”]X5; 72C-10’), the corresponding primers were
then added at a final concentration of 10uM and the tube
was cycled for 25 cycles at the same cycling conditions.
The PCR product was purified, digested with HindIII and
SacI and ligated, using T4 DNA ligase, to the BstΔTAR
construct cut with the same enzymes. For the point muta-
tions, the primers used were: Fwd: TGTGAAGCTTTCG
GAGGACAGTACTC and Rev TGTGGAGCTCGGATCT
GGTCTAAC. To make the point mutation constructs,
each of the oligo pairs for constructs K- P (see Table 2) was
added at a final concentration of 10 mM to a PCR mix with
only the reverse primer, at a final concentration of 1uM
and the reaction was amplified for 10 cycles at the follow-
ing conditions: (94C, 2’30”; [94C-1’, 55C-1’, 72C- 1’45”]
X10; 72C-10’). Following this, the forward primer was
added at a final concentration of 1uM, and the reaction
mixture was cycled 25 more times at the same conditions.
The PCR product was purified, digested with HindIII and
SacI and ligated, using T4 DNA ligase, to the BstΔTAR
construct cut with the same enzymes. The sequences of all
constructs were confirmed by sequencing with the primer
5’CGCTGGGCCCTTCTTAA, present on the luciferase
gene or with the primer 5':CAGCTGAACGGTCTGGT
TATAG present on the CAT gene. CMV-Renilla lucifer-
ase (Promega, Madison, WI) was used as transfection
control.
Cells, cell culture and CAF preparations
293 T cells were obtained from the ATCC and cultured
in DMEM, supplemented with 10% FBS, 2 mM Gluta-
mine and 1 mM sodium pyruvate. TZM-bl cells wereDNA oligos used
GGTCGAAGGGAGGCGTGGCCTGAGCCCTCAGATCCTGCATATAAGC
And
CAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCCGAGC
AAGGGAGGCGTGGCCTGGGCGGGACTGAGCCCTCAGATCCTGCATATAAGC
And
CAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCCGAGC
GAAGGGAGGCGTGGCCTTGGGGAGTGGCGAGCCCTCAGATCCTGCATATAA
And
CAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCCGAGC
GTACTC, Rev: TGTGGAGCTCGGATCTGGTCTAAC.
Table 2 SpI inactivating point mutation construct oligos and primers
3 2 1 Construct
mut Wt wt K
mut Wt mut L
mut Mut wt M
wt Mut wt N
wt Mut mut O
wt Wt mut P
Construct Oligos used (Oligo 2 is the same for all constructs)
K Oligo 1: TCGGAGGACAGTACTCCGACCCGGTCGAAGGGATTCGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCCCTCAGATCCTGCATATAA
Oligo 2: GAGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCCGAGC
L Oligo 1: TCGGAGGACAGTACTCCGACCCGGTCGAAGGGATTCGTGGCCTGGGCGGGACTGGTTAGTGGCGAGCCCTCAGATCCTGCATATAA
M Oligo 1: TCGGAGGACAGTACTCCGACCCGGTCGAAGGGATTCGTGGCCTGTTCGGGACTGGGGAGTGGCGAGCCCTCAGATCCTGCATATAA
N Oligo 1: TCGGAGGACAGTACTCCGACCCGGTCGAAGGGAGGCGTGGCCTGTTCGGGACTGGGGAGTGGCGAGCCCTCAGATCCTGCATATAA
O Oligo 1: TCGGAGGACAGTACTCCGACCCGGTCGAAGGGAGGCGTGGCCTGTTCGGGACTGGTTAGTGGCGAGCCCTCAGATCCTGCATATAA
P Oligo 1: TCGGAGGACAGTACTCCGACCCGGTCGAAGGGAGGCGTGGCCTGGGCGGGACTGGTTAGTGGCGAGCCCTCAGATCCTGCATATAA
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Reagent Program, Division of AIDS, NIAID, NIH: TZM-
bl from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tran-
zyme Inc. The CD8+ T cell line, TG, was previously
established by Herpes virus saimiri (HVS)-transform-
ation of CD8+ T cells from a chronically HIV-1 infected
subjected from the MACS. TG cells were grown in
RPMI with 20% FBS (100 nm filtered, Invitrogen Life
Sciences, Carlsbad, CA), supplemented with 25 mM
HEPES, Penicillin (100 U/mL) and Streptomycin (100
ug/mL) and rIL2 (50 U/mL, Roche Diagnostics). CAF
from these transformed CD8+ T cells was prepared as
described before [8]. Briefly, TG cells were cultivated for
14 days, after which, the cells were centrifuged at 300 g
and the resulting supernatant was then further centri-
fuged at 4°C at the following speeds: 2000 g for 30 mi-
nutes, 6000 g for 20 minutes and 15000 g for 1 hour to
remove other debris. This conditioned media was used
for further investigations on CAF.
Transfections
293 T cells were plated at a concentration of either
200,000 cells/mL in a 6- well plate (if the reporter gene
assay was CAT), or 20,000 cells/100 uL in a 96-well plate
(if the reporter gene assay was luciferase), in triplicate.
24 hours after plating, 10% vol/vol of CAF from TG cells
was added to the culture. 24 hours later, either 1ug or
10 ng (depending on whether the assay was for CAT or lu-
ciferase respectively) of the relevant plasmid/s was trans-
fected into all cells, using Lipofectamine Plus (Invitrogen,
Carlsbad, CA), according to manufacturer’s instructions,
along with the transfection control, CMV-Renilla plasmid.
24 hours following transfection, the cells were stimulated
with 100 ng/mL phorbolmyristoylacetate (PMA) for18 hours or 6 hours (depending of whether the assay was
for CAT or luciferase respectively), after which they were
lysed and the reporter gene product was measured. Meas-
urement of the reporter gene was done after normalizing
for total protein content and Renilla expression. For the
experiment detailed in Figure 5, with ICP0 to boost tran-
scription of the Mnl construct, 293 T cells were plated at a
density of 200,000/mL in a 6 well plate, in triplicate.
24 hours after plating, 10% vol/vol of CAF from TG cells
was added to the culture. 1ug of Mnl-CAT with or with-
out 0.5 ug of ICP0 expression plasmid was transfected,
into designated wells. Expression from the Mnl-LTR con-
struct was induced either with co-transfection with CMV-
tat expression plasmid (0.5 ug per well) or with PMA
(100 ng/mL for 18 hours). CMV-renilla was transfected as
a control. 36 hours after transfection, cells were lysed and
CAT protein content quantified after normalizing for total
protein (as measured by Bradford Assay) and Renilla lucif-
erase levels. CAT and luciferase protein expressions were
quantified by CAT ELISA (Roche) and Bright Glo systems
(Promega), respectively, according to manufacturer’s in-
structions. Renilla content was measured using Stop-and-
Glo kit (Promega).
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